The objective of the Medicinal Chemistry/Drug Discovery & Development India (MCADDI) project is to build and optimize a basic drug discovery course for industrial and academic scientists, including Medicinal Chemists, in India and other South Asian countries. The success of the 2017 program, partly supported by an IUPAC project (#2016-009-1-700), and the feedback from the Industry and Academic groups strongly encourages us to continue our theme of applied chemistry education in relation to drug design and development. Biocon Academy (Bangalore, India) has generously agreed to host this event again in 2019 and will provide the access to their facility for the faculty and attendees.
This 5-day course will broaden the focus of the program compared to the 2017 Course by adding new lectures on the use of Heterocyclic Chemistry and Fluorine Chemistry in Drug Discovery, and adding a lecture on drug delivery. The first part session of the Course will be focused on the fundamentals of drug discovery and the second part will be focused on the application of new technologies in the design and development process. The 2019 program will dedicate a full day session to the discovery and development of biologic drugs, including antibodies, antibody-drug conjugates and therapeutic proteins. The increase in medicinal chemistry employment in Indian and southeast Asian pharmaceutical companies, and in Contract Research Organizations (CROs) collaborating with US and European companies, has created a vital need for chemists to acquire state of the art knowledge of medicinal chemistry. The performance and value of the MCADDI courses (2013, 2015, 2017) has been assessed by the participants and faculty, and has received positive feedback from both industrial and academic scientist in India. The 2019 course will also be assessed to determine whether to continue in the same format, or evolve the course further.. The desired outcome will be to enroll new and broader set of drug discovery scientists from industry and academia. The number of participants would be about 100 from academic and industry similar to the attendance in 2017, and the goal is to provide participants with a strong introduction to the fundamentals and practice of medicinal chemistry in drug discovery, including the use of tools such as computer-assisted drug design (CADD) and automated synthesis. Continued support to complete this pilot program will allow us to build on the success of the 2017 Course. We are planning to actively seek the participation of scientists from other South Asian countries such as Singapore, Malaysia, South Africa etc.
For more details about the MCADDI program, see https://mcaddi.com
The increase in medicinal chemistry employment in Indian and Southeast Asian pharmaceutical companies and in the Contract Research Organizations collaborating with US and European companies has created a need for chemists to acquire state-of-the-art knowledge of medicinal chemistry. This course will emphasize the design strategy that takes into account of the DMPK and toxicophore in small molecules as well as the fundamentals of Biologics and Development of Biologics drugs. In addition the role of Heterocyclic Chemistry and Fluorine Chemistry in Drug Discovery and development with be emphasized. The MCADDI 2019 course will be based on the successful first year program in 2017 and the Drew University Residential School on Medicinal Chemistry, taught annually since 1986 on the Drew University campus in Madison, New Jersey (https://www.drew.edu/resmed/). MCADDI will comprise 4.5 days of content, including 18-20 1-hour lectures on topics covering all aspects of medicinal chemistry from target selection and validate to hit identification, hit-to-lead chemistry, and lead optimization. New lectures on Heterocyclic Chemistry and fluorine chemistry will be added for the 2019 program. In line with the current development in Biologics space in drug discovery, we will have a full day session on Biologics topics. Four case history presentations of successful drug discovery programs will also be included. The Course in 2019 will be taught mainly by faculty from the US, with some local Indian faculty members also participating. The plan is to increase the number of Indian faculty members in subsequent years. The performance and value of the MCADDI course will be assessed after the 2019 program, and a decision whether to continue in the same format made at that time. The desired outcome will be to enroll 80-100 attendees each year, and provide them with a strong introduction to the practice of medicinal chemistry in drug discovery and development.
Page last update 20 June 2018